After studying the liver biopsies of NAFLD patients, it was stated that MALAT1 acts as a regulator of hepatic inflammation and fibrosis and of insulin resistance by targeting the C-X-C motif chemokine ligand 5 (CXCL5). This evidence concerns the gene MALAT1 and metabolic dysfunction-associated steatotic liver disease.